ZA201008484B - Rasagiline for parkinson's disease modification - Google Patents

Rasagiline for parkinson's disease modification

Info

Publication number
ZA201008484B
ZA201008484B ZA2010/08484A ZA201008484A ZA201008484B ZA 201008484 B ZA201008484 B ZA 201008484B ZA 2010/08484 A ZA2010/08484 A ZA 2010/08484A ZA 201008484 A ZA201008484 A ZA 201008484A ZA 201008484 B ZA201008484 B ZA 201008484B
Authority
ZA
South Africa
Prior art keywords
rasagiline
parkinson
disease modification
disease
modification
Prior art date
Application number
ZA2010/08484A
Other languages
English (en)
Inventor
Ruth Levy
Eliav Eyal
Tamar Goren
Sheila Oren
Naim Sayag
Yonatan Weiss
Miri Ben-Ami
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of ZA201008484B publication Critical patent/ZA201008484B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA2010/08484A 2008-06-13 2010-11-25 Rasagiline for parkinson's disease modification ZA201008484B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13193608P 2008-06-13 2008-06-13
US18972408P 2008-08-22 2008-08-22
PCT/US2009/003528 WO2009151625A1 (en) 2008-06-13 2009-06-12 Rasagiline for parkinson's disease modification

Publications (1)

Publication Number Publication Date
ZA201008484B true ZA201008484B (en) 2012-05-30

Family

ID=41415378

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/08484A ZA201008484B (en) 2008-06-13 2010-11-25 Rasagiline for parkinson's disease modification

Country Status (13)

Country Link
US (2) US20090312436A1 (enExample)
EP (2) EP2296462A4 (enExample)
JP (3) JP2011522892A (enExample)
CN (2) CN103893160A (enExample)
AU (2) AU2009258151A1 (enExample)
BR (1) BRPI0909894A2 (enExample)
CA (1) CA2727022A1 (enExample)
EA (1) EA201170018A1 (enExample)
IL (1) IL209131A0 (enExample)
MX (1) MX2010013766A (enExample)
NZ (1) NZ589445A (enExample)
WO (1) WO2009151625A1 (enExample)
ZA (1) ZA201008484B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060018957A1 (en) * 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline
ES2371883T3 (es) * 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
US8809310B2 (en) * 2006-02-21 2014-08-19 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
AU2007235517B2 (en) 2006-04-03 2013-01-31 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Restless Legs Syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EA201070842A1 (ru) * 2008-01-11 2011-04-29 Тева Фармасьютикал Индастриз, Лтд. Препаративные формы разагилина, их получение и применение
AU2009258120B2 (en) * 2008-06-10 2014-11-27 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
JP2011525489A (ja) * 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
NZ589547A (en) 2008-06-19 2013-03-28 Teva Pharma Dried rasagiline base having a water content less than 0.5 % by weight
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
PT2451771E (pt) 2009-07-09 2014-09-19 Ratiopharm Gmbh Sais de rasagilina e suas preparações farmacêuticas
WO2011087791A1 (en) * 2009-12-22 2011-07-21 Teva Pharmaceutical Industries Ltd. 3-keto-n-propargyl-1-aminoindan
RU2587330C2 (ru) * 2010-07-27 2016-06-20 Тева Фармасьютикал Индастриз Лтд. Применение разагилина для лечения обонятельной дисфункции
WO2012015946A1 (en) * 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersion of rasagiline citrate
CN103188933A (zh) * 2010-10-26 2013-07-03 泰华制药工业有限公司 富集氘的雷沙吉兰
CA2732440C (en) * 2011-02-23 2017-10-31 Universite Laval Cystamine analogues for the treatment of parkinson`s disease
CA2851433A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-methyl-propargyl-aminoindan
BR112014008555A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-formil-propargil-aminoindano
US20130089611A1 (en) * 2011-10-10 2013-04-11 Teva Pharmaceutical Industries, Ltd. Rasagiline citramide
AR092168A1 (es) 2012-08-17 2015-03-25 Teva Pharma Formulaciones parenterales de rasagilina
CA2943841A1 (en) * 2014-04-01 2015-10-08 Teva Pharmaceutical Industries Ltd. Determination of single nucleotide polymorphisms useful to predict response for rasagiline
EP3432931A1 (en) * 2016-03-26 2019-01-30 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositons for n-propargylamine derivative
EP3606541A1 (en) * 2017-04-05 2020-02-12 Crestovo Holdings LLC Compositions and methods for treating parkinson's disease (pd) and related disorders
CA3127590A1 (en) * 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof
GB202109826D0 (en) * 2021-07-07 2021-08-18 Bial Portela & Ca Sa Treatment regimens for early idiopathic parkinson's disease

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
CN1031995C (zh) * 1991-01-02 1996-06-12 奥韦特有限公司 N-炔丙基-1-氨基茚满的r-对映体的制法
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
CA2275425C (en) * 1996-12-18 2009-08-04 Michael Chorev Aminoindan derivatives
AU2002319615A1 (en) * 2001-07-20 2003-03-03 Mount Sinai School Of Medicine Of New York University Methods for diagnosing and treating alzheimer's disease and parkinson's disease
CA2471760A1 (en) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Preventives/remedies for urinary disturbance
SI1567152T1 (sl) * 2002-11-15 2013-10-30 Teva Pharmaceutical Industries Ltd. Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US20060018957A1 (en) * 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline
ES2371883T3 (es) * 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
US7815942B2 (en) * 2005-02-23 2010-10-19 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
US7491847B2 (en) * 2005-11-17 2009-02-17 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) * 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
US8809310B2 (en) * 2006-02-21 2014-08-19 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
AU2007235517B2 (en) * 2006-04-03 2013-01-31 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Restless Legs Syndrome
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
UA97382C2 (ru) * 2006-12-14 2012-02-10 Тева Фармасьютікл Індастріз, Лтд. Таннат разагилина
AU2007334428B2 (en) * 2006-12-14 2014-05-29 Teva Pharmaceutical Industries, Ltd. Crystalline solid rasagiline base
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
WO2009032202A1 (en) * 2007-08-29 2009-03-12 Nuon Therapeutics, Inc. Treatment of brain disorders
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EA201070842A1 (ru) * 2008-01-11 2011-04-29 Тева Фармасьютикал Индастриз, Лтд. Препаративные формы разагилина, их получение и применение
AU2009258120B2 (en) * 2008-06-10 2014-11-27 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
NZ589547A (en) * 2008-06-19 2013-03-28 Teva Pharma Dried rasagiline base having a water content less than 0.5 % by weight
JP2011525489A (ja) * 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
DE102008064061A1 (de) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
JP2013507352A (ja) * 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
WO2011087791A1 (en) * 2009-12-22 2011-07-21 Teva Pharmaceutical Industries Ltd. 3-keto-n-propargyl-1-aminoindan

Also Published As

Publication number Publication date
MX2010013766A (es) 2011-03-15
JP2017081938A (ja) 2017-05-18
NZ589445A (en) 2013-06-28
EA201170018A1 (ru) 2011-08-30
JP2011522892A (ja) 2011-08-04
AU2016259315A1 (en) 2016-12-01
CN103893160A (zh) 2014-07-02
AU2009258151A1 (en) 2009-12-17
CN102065687A (zh) 2011-05-18
EP2296462A4 (en) 2011-06-15
WO2009151625A1 (en) 2009-12-17
JP2015096532A (ja) 2015-05-21
BRPI0909894A2 (pt) 2015-07-28
EP2666356A1 (en) 2013-11-27
CA2727022A1 (en) 2009-12-17
IL209131A0 (en) 2011-01-31
EP2296462A1 (en) 2011-03-23
US20140243418A1 (en) 2014-08-28
US20090312436A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
IL209131A0 (en) Rasagiline for parkinson's disease modification
ZA201002751B (en) Compositions for treating parkinson's disease
IL209896A0 (en) Compounds for treating symptoms associated with parkinson's disease
ZA201006127B (en) 4'4'-dioxaspiro-spirocyclically substituted tetramates
PL2985032T3 (pl) Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona
PT2197883E (pt) Derivados de catecolamina úteis para o tratamento da doença de parkinson
WO2011044537A9 (en) Methods for treating alzheimer's disease
IL213120A0 (en) Method for treating parkinson' s disease
IL217149A0 (en) Compositions and methods for treating parkinson's disease
HK1156186A (en) Rasagiline for parkinson's disease modification
GB0822289D0 (en) "BABOO"babyseat carry
HK1175364A (en) Methods for treating parkinson's disease
GB0916264D0 (en) Diagnostic agent for parkinson's disease
AU2007905305A0 (en) Biomarkers for Parkinson's disease
HK1147194A (en) Compositions for treating parkinson's disease
GB0717956D0 (en) 20's
AU2008905035A0 (en) Alzheimer's disease biomarkers
GB0707985D0 (en) Easy's
IL206998A0 (en) Vaccine for alzheimer's disease
GB0821104D0 (en) Ivn 01
GB0808545D0 (en) Note 200009
GB0805897D0 (en) Note 10001
GB0808549D0 (en) Note 200004
GB0808553D0 (en) Note 200014
GB0808548D0 (en) Note 200005